MIGRAINE REFERENCES

Timothy C. Hain, MD, Chicago IL. Page last modified: March 5, 2011

We moved these references out of our main migraine page to make the main content easier to print.

• Causes
• Children
• treatment
• Rebound
• White matter lesions
• Epidemiology

Migraine causes:

• Asghar, M. S., A. E. Hansen, et al. (2011). "Evidence for a vascular factor in migraine." Annals of neurology 69(4): 635-645.
• Da Silva A, Granziera C, Snyder J, Hadjikhani M. Thickening of somatosensory cortex of patients with Migraine. Neurology 2007, 69, 1990-1995
• Denuelle M, and others.  A PET study of photophobia during spontaneous migraine attacks.  Neurology 2011:76:213-218
• Evans RW, Olesen J. Migraine classification, diagnostic criteria and testing. Neurology 2003:60(Suppl 2) 24-30
• Gasbarrini A, and others. Beneficial effects of Helicobacter pylori eradication on migraine. Hepatogastroenterology, 1998;45:765-70
• Goadsby PH. Migraine, aura and spreading depression: Why are we still talking about it ? Ann Neurol, 2001, 59, 5-6.
• Lipton RB and others. Migraine in the United States. Epidemiology and patterns of health care use. Neurology 2002:58:885-894
• Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological and therapeutic data. Cephalgia 1998:18:1874-82
• Mitsikostas DD, Sfikakis PP and Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth(Brain, Vol. 127, No. 5, 1200-1209, 2004)
  
• Meyer JS et al. Reversible cognitive decline accompanies migraine and cluster headache. Headache 2000:40:638-646
• Rozen et al. Increasing incidence of medically recognized migraine headache in a United States population. Neurology 1999:53:1468-1473
• Silberstein SD. Practice parameter: evidence based guidelines for migraine headache (an evidence-based review). Neurology 2000:55:754-763
• Schreiber CP and others. Prevalence of migraine in patients with a history of self-reported or physician diagnosed "Sinus" headache. Arch Int Med. 2004: 164: 1769-1772
• Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population based studies. Neurology 44 (suppl 4) S17-S23, 1994
• Tzourio C and others. Association between migraine and endothelin type A receptor (ETA-231 A/G) gene polymorphism. Neurology 2001:56;1273-1277

Migraine in children

• Bille B: Migraine in School Children. Acta Pediatrifa 51 (s136) 3-151, 1962
• Mortimer MJ et al. Develop Med and Child Neurol 34:1095-1101, 1992.
• Mortimer MJ et al. Headache 33;427-431, 1993

Migraine treatment:

• Bisdorf A. Treatment of migraine associated vertigo with Lamotrigine. An observational study. Bull Soc Sci Med, 2004, 103-108. Comment: an uncontrolled study of 19 individuals.
• Boska M.D. and others. Contrasts in cortical magnesium ... between migraine syndromes. Neurology 2002:58:1227-1233
• Charles A, Flippen C, Romero Reyes M, Brennan KC.J Headache Pain. 2007 Sep;8(4):248-50. Epub 2007 Sep 24. Memantine for prevention of migraine: a retrospective study of 60 cases.
  Cutrer FM, Limmoth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalgia 1997:17:93-100
• Farkkila, M., J. Olesen, et al. (2003). "Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan." Cephalalgia 23(6): 463-71.
• Geroud G, Keywood C, Senared JM. Migraine headache recurrence ... Headache 2003:43:376-388
• Krusz J-C. Oxcarbazepine is effective in chronic migraine prophylaxis (abstract). Cephalagia 2000;20(4):425. Abstract 394
• Maassenvandenbrink et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998:98:25-30.
• Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological and therapeutic data. Cephalgia 1998:18:1874-82
• Ryan R and others. Neurology 1997:49:1225-1230
• Foster CA, Bafaloukos J. paroxetine in the treatment of chronic daily headache. Headache 1994:34(10):587-9
• Gaist D and others. Inappropriate use of sumatriptan: population-based register and interview study. BMJ 1998, 316, 1352-3
• Goadsby PJ, Hoskin KH. Ann Neurol 1998:43:711-718
• Goadsby PJ., Lipton RB, Ferrari MD. Migraine -- current understanding and treatment. NEJM Jan 24, 2002, p 261
• Jenson M et al. Efficacy of oxcarbazepine in migraine: a prospectice open label trial (abstract). Ann meeting of the Am. Headache Society, 2002, Jun 21-23, Abstract S-96
• Limroth V, Kazarawa Z, Fritsche G, Diener H. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan.
• Langemark M, lesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind study. Headache 1994;31(1):20-4
• Lipton and others. Sumatriptan for the range of headaches in migraine sufferers: results of the spectrum study. Headache 2000:40, #10)
• Lipton and many others. Cutaneous allodynia in the migraine population. Ann Neurol 2008;63:148-158
• Maasenvabdebrrink et al. 5-Ht1b receptor polymorphism and clinical response to sumatriptan. Headache 1998:38:288-291. Comment: 5HT-1b Receptor polymorphism does not explain response variability.
• Nett RB, Krusz JC. Oxcarbazepine prophylaxis for chronic migraine and tension-type headache (abstract). Cephalgia 2002:22(7); 608-PB.35
• Peeters M, Gunthorpe MJ, Strijbos PJ, Goldsmith P, Upton N, James MF.J Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.Pharmacol Exp Ther. 2007 May;321(2):564-72. Epub 2007 Jan 31.
• Sandrini, G., M. Farkkila, et al. (2002). "Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study." Neurology 59(8): 1210-7.
• Silberstein SD. Practice parameter: evidence based guidelines for migraine headache (an evidence-based review). Neurology 2000:55:754-763
• Silberstein et al, Acute migraine treatment with droperidol: A randomized double-blind placebo-controlled trial. Neurology 60, p315-321, 2003
• Yu W, ZHorowitz S. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 2003:60:120-121

Rebound headache

• Seminars in Headache Medicine, Analgesic Rebound Headache, Vol #2, #3, Sept 1997.
• Begal M, Liptan R. Excessive acute migraine medication use and migraine progression. Neurology 2008:71:1821-1828
• Napoli and many others. Vascular smooth muscle cell dysfunction in patients with migraine. Neurology 2009;72; 2111-2114

White matter lesions in migraine

• Dahlof, C. G., P. Linton-Dahlof, et al. (2005). "[Is migraine a progressive cerebral disease?]." Neurologia 20(7): 356-65.
• De Benedittis, G., A. Lorenzetti, et al. (1995). "Magnetic resonance imaging in migraine and tension-type headache." Headache 35(5): 264-8.

Migraine epidemiology

• Manback A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors and consequences of remission from chronic migraine to episodic migraine. Neurology 2011;76:711-718